Evidence map›Paper›PMID 41983135›Full record

SynthesisFrontiers in immunology2026

Safety and efficacy of anti-IL-5 monoclonal antibodies as second-line therapy for chronic rhinosinusitis with nasal polyps: a meta-analysis.

Huixiu Liao, Chaohong Qiu, Yingying Luo, Jiaru Chen, Congyu Qin, Jieru Quan, Weiming Liang, Jiongying Qin, Rui Chen

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huixiu LiaoThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Chaohong QiuDepartment of Otolaryngology, Rongshui Miao Autonomous County People's Hospital, Liuzhou, Guangxi, China.
Yingying LuoThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Jiaru ChenThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Congyu QinThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Jieru QuanSchool of Economics and Management, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Weiming LiangThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Jiongying QinThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.
Rui ChenThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This meta-analysis aimed to evaluate the safety and efficacy of anti-IL-5 monoclonal antibody (anti-IL-5 mAb) as a second-line therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). Materials and methods: Four databases (PubMed, Web of Science, Embase and Cochrane Library) were searched from the establishment of the databases to September 15, 2025, for randomized controlled trials (RCTs) comparing anti-IL-5 mAb versus placebo in the treatment of CRSwNP. The primary outcome measure of this meta-analysis were nasal polyp score (NPS) and Sino-Nasal Outcome Test-22 (SNOT-22) score. Secondary outcome measures included nasal blockage score (NBS), loss of smell score (LSS), Lund-Mackay score (LMS), University of Pennsylvania Smell Identification Test (UPSIT) score, nasal overall visual analog scale(VAS) score, nasal composite visual analog scale(VAS) score, number of first-time NP surgery patients and number of systemic corticosteroids (≥1 course) patients. Results: Totally 10 RCTs were included for meta-analysis. Compared with placebo, anti-IL-5 mAb provided a significantly lower NPS (WMD = -0.58, 95%CI: -0.70 ~ -0.46, P < 0.00001, I Conclusions: This results confirmed that anti-IL-5 mAb therapy was safe and effective for CRSwNP and can serve as a second-line therapy. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251170717.

Indexed as

Antibodies, MonoclonalInterleukin-5Nasal PolypsRhinosinusitisChronic DiseaseHumansRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, MonoclonalIL5 protein, humanInterleukin-5anti-IL-5 monoclonal antibodieschronic rhinosinusitis with nasal polypsmeta-analysisnasal polyp scoresecond-line therapy

Identifiers

PMID41983135
PMCPMC13070943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.